Autolus Therapeutics appoints Matthias Will, M.D. as Chief Development Officer

Autolus Therapeutics plc

Dr. Will joins as CDO effective September 30, 2024.
Previously CMO at Dren Bio and VP Clinical Development at CRISPR Therapeutics.
Will lead development organization, including obe-cel for relapsed/refractory adult B-ALL.
Appointment comes as Autolus prepares to commercialize first product obe-cel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.